JPS6229514A - 医薬活性物質の遅延放出形粒状物及びその製造方法 - Google Patents
医薬活性物質の遅延放出形粒状物及びその製造方法Info
- Publication number
- JPS6229514A JPS6229514A JP61177897A JP17789786A JPS6229514A JP S6229514 A JPS6229514 A JP S6229514A JP 61177897 A JP61177897 A JP 61177897A JP 17789786 A JP17789786 A JP 17789786A JP S6229514 A JPS6229514 A JP S6229514A
- Authority
- JP
- Japan
- Prior art keywords
- active substance
- delayed release
- granules
- mixture
- release granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008187 granular material Substances 0.000 title claims description 61
- 239000013543 active substance Substances 0.000 title claims description 54
- 230000003111 delayed effect Effects 0.000 title claims description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 claims description 54
- 239000011248 coating agent Substances 0.000 claims description 33
- 238000000576 coating method Methods 0.000 claims description 33
- 238000010438 heat treatment Methods 0.000 claims description 30
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical group [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 17
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical group [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- 235000013024 sodium fluoride Nutrition 0.000 claims description 10
- 239000011775 sodium fluoride Substances 0.000 claims description 10
- 239000000454 talc Substances 0.000 claims description 10
- 229910052623 talc Inorganic materials 0.000 claims description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims description 9
- 239000007931 coated granule Substances 0.000 claims description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims description 9
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- 229960002819 diprophylline Drugs 0.000 claims description 4
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- KYHQZNGJUGFTGR-LURJTMIESA-N 7-[(2s)-2-hydroxypropyl]-1,3-dimethylpurine-2,6-dione Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C[C@@H](O)C KYHQZNGJUGFTGR-LURJTMIESA-N 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 239000002216 antistatic agent Substances 0.000 claims description 3
- 229960001992 dimetindene Drugs 0.000 claims description 3
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical group CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000008240 homogeneous mixture Substances 0.000 claims description 3
- 229960004767 proxyphylline Drugs 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical class 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229960000851 pirprofen Drugs 0.000 claims 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical group ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
- 235000005493 rutin Nutrition 0.000 claims 1
- 239000008188 pellet Substances 0.000 description 25
- 239000007921 spray Substances 0.000 description 16
- 239000006185 dispersion Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- 239000002245 particle Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- 239000011859 microparticle Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 description 7
- 229940099401 dimethindene maleate Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000010724 Wisteria floribunda Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000003305 rutin Chemical class 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 238000012430 stability testing Methods 0.000 description 3
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 102220289725 rs778831047 Human genes 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- -1 Aerosil Chemical compound 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100469268 Caenorhabditis elegans rpl-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical group CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101100208039 Rattus norvegicus Trpv5 gene Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
- 239000004815 dispersion polymer Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001184 hypocalcaemic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- RQXCLMGKHJWMOA-UHFFFAOYSA-N pridinol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 RQXCLMGKHJWMOA-UHFFFAOYSA-N 0.000 description 1
- 229960003195 pridinol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960003232 troxerutin Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8519310 | 1985-07-31 | ||
| GB858519310A GB8519310D0 (en) | 1985-07-31 | 1985-07-31 | Granular active substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6229514A true JPS6229514A (ja) | 1987-02-07 |
Family
ID=10583125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61177897A Pending JPS6229514A (ja) | 1985-07-31 | 1986-07-30 | 医薬活性物質の遅延放出形粒状物及びその製造方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4728513A (en, 2012) |
| JP (1) | JPS6229514A (en, 2012) |
| AT (1) | AT392901B (en, 2012) |
| AU (1) | AU596804B2 (en, 2012) |
| BE (1) | BE905200A (en, 2012) |
| CH (1) | CH670566A5 (en, 2012) |
| DE (1) | DE3625458A1 (en, 2012) |
| DK (1) | DK361786A (en, 2012) |
| ES (1) | ES2000577A6 (en, 2012) |
| FI (1) | FI863074A7 (en, 2012) |
| FR (1) | FR2585570B1 (en, 2012) |
| GB (2) | GB8519310D0 (en, 2012) |
| GR (1) | GR862017B (en, 2012) |
| HU (1) | HU196304B (en, 2012) |
| IL (1) | IL79537A (en, 2012) |
| IT (1) | IT1195985B (en, 2012) |
| LU (1) | LU86523A1 (en, 2012) |
| NL (1) | NL8601961A (en, 2012) |
| NZ (1) | NZ217028A (en, 2012) |
| PH (1) | PH23531A (en, 2012) |
| PT (1) | PT83093B (en, 2012) |
| SE (1) | SE8603247L (en, 2012) |
| ZA (1) | ZA865691B (en, 2012) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01502754A (ja) * | 1987-03-27 | 1989-09-21 | ザ ウエルカム フアウンデーション リミテッド | 薬学的製剤 |
| WO2006059716A1 (ja) * | 2004-12-03 | 2006-06-08 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| JP2007510516A (ja) * | 2003-11-10 | 2007-04-26 | コナー メドシステムズ， インコーポレイテッド | 複数溶剤システムによって形成された有益な作用物質マトリクスを有する拡張可能医療デバイス |
| JP5283623B2 (ja) * | 2007-07-17 | 2013-09-04 | 旭化成ケミカルズ株式会社 | 水系組成物 |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4726952A (en) * | 1983-08-11 | 1988-02-23 | Mission Pharmacal | Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis |
| EP0272265B1 (de) * | 1985-09-25 | 1991-05-22 | Gergely, Gerhard, Dr. | Zerfallstablette und verfahren zu ihrer herstellung |
| CH669523A5 (en, 2012) * | 1986-06-25 | 1989-03-31 | Mepha Ag | |
| US4859467A (en) * | 1986-09-25 | 1989-08-22 | Colgate-Palmotive Company | Sustained release fluoride composition |
| GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
| DE3712095A1 (de) * | 1987-04-10 | 1988-10-20 | Lentia Gmbh | Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe |
| US5178868A (en) * | 1988-10-26 | 1993-01-12 | Kabi Pharmacia Aktiebolaq | Dosage form |
| IT1227899B (it) * | 1988-12-23 | 1991-05-14 | Poli Ind Chimica Spa | Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni |
| US4970081A (en) * | 1989-01-03 | 1990-11-13 | Sterling Drug Inc. | Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith |
| IE69270B1 (en) * | 1989-01-03 | 1996-08-21 | Sterling Winthrop Inc | Controlled-release low-dose aspirin |
| US5084287A (en) * | 1990-03-15 | 1992-01-28 | Warner-Lambert Company | Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat |
| US5013728A (en) * | 1990-05-04 | 1991-05-07 | Colgate - Palmolive Company | Composition for treating osteoporosis and hormonal imbalance |
| US5153005A (en) * | 1990-12-11 | 1992-10-06 | Colgate-Palmolive Company | Composition and method for preventing fluorosis |
| US6613332B1 (en) | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
| ES2109362T3 (es) * | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US7070806B2 (en) * | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| FI101039B (fi) * | 1992-10-09 | 1998-04-15 | Eeva Kristoffersson | Menetelmä lääkepellettien valmistamiseksi |
| US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
| CA2086631C (en) * | 1992-12-22 | 1998-10-06 | J. Gabriel Michael | Oral administration of immunologically active biomolecules and other therapeutic proteins |
| DE4319649A1 (de) * | 1993-03-18 | 1994-09-22 | Asta Medica Ag | Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe |
| US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
| US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
| US5843480A (en) * | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| US20020006438A1 (en) * | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
| US5674529A (en) * | 1995-06-06 | 1997-10-07 | Church & Dwight Co., Inc. | Alkalinizing potassium salt controlled release preparations |
| FR2760190B1 (fr) * | 1997-02-28 | 1999-04-09 | Adir | Composition pharmaceutique pour la liberation programmee de dexfenfluramine |
| DK1009387T3 (da) | 1997-07-02 | 2006-08-14 | Euro Celtique Sa | Stabiliserede tramadolformuleringer med langvarig frigivelse |
| US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
| FR2785539B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Particules enrobees d'ibuprofene cristallin granule |
| DE19928312A1 (de) * | 1999-06-16 | 2000-12-21 | Schering Ag | Arzneimittelzubereitung mit verzögerter Wirkstoffabgabe |
| EP1207860B1 (en) | 1999-09-02 | 2007-10-24 | Nostrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
| EP2305218A1 (en) | 1999-10-29 | 2011-04-06 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| WO2002036099A1 (en) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
| DE10152469A1 (de) * | 2001-10-24 | 2003-06-26 | Gruenenthal Gmbh | 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| US7410965B2 (en) * | 2002-05-29 | 2008-08-12 | Gruenenthal Gmbh | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol |
| US7387793B2 (en) * | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| WO2005095950A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Method and device for evaluation of pharmaceutical compositions |
| DE102004035938A1 (de) * | 2004-07-23 | 2006-02-16 | Röhm GmbH & Co. KG | Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil |
| ES2550626T5 (es) * | 2005-02-25 | 2019-01-15 | Takeda Pharmaceuticals Co | Método para producir gránulos |
| CA2671197A1 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
| DE102006051020A1 (de) * | 2006-10-26 | 2008-04-30 | Evonik Röhm Gmbh | Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung |
| US20100062073A1 (en) * | 2006-11-29 | 2010-03-11 | Ronald Arthur Beyerinck | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein |
| WO2008125940A2 (en) * | 2007-04-17 | 2008-10-23 | Pfizer Products Inc. | Nanoparticles comprising non-crystalline drug |
| WO2008135828A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
| WO2008135855A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
| US20100080852A1 (en) * | 2007-05-03 | 2010-04-01 | Ronald Arthur Beyerinck | Phamaceutical composition comprising nanoparticles and casein |
| US20080279930A1 (en) * | 2007-05-07 | 2008-11-13 | Bernd Terhaag | Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof |
| EP2162120B1 (en) * | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
| US9545384B2 (en) | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
| US20100215747A1 (en) * | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
| US9724362B2 (en) * | 2007-12-06 | 2017-08-08 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
| EP2240162A4 (en) * | 2007-12-06 | 2013-10-09 | Bend Res Inc | NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER |
| CN103432093B (zh) * | 2013-08-31 | 2015-03-25 | 西南大学 | 甲磺酸普立地诺骨架缓释片及其制备方法 |
| CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US904848A (en) * | 1908-05-27 | 1908-11-24 | William W Devore | Artificial whirlpool. |
| AT64577B (de) * | 1913-04-28 | 1914-04-25 | Carl Georg Rodeck | Volksbelustigungsvorrichtung mit sich drehenden Plattformen. |
| US1689138A (en) * | 1927-10-15 | 1928-10-23 | Playground & Gymnasium Equipme | Bathers' inclined rotary water platform |
| NL280825A (en, 2012) * | 1962-07-11 | |||
| DE2010110A1 (de) * | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrokapseln mit Hilfe von synthetischen Koazervaten |
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| JPS52139715A (en) * | 1976-05-14 | 1977-11-21 | Nippon Kayaku Co Ltd | Coated granules of alkali polyacrylate |
| EP0052075A1 (de) * | 1980-11-12 | 1982-05-19 | Ciba-Geigy Ag | Körnige Arzneimittel-Retardform |
| JPS5867616A (ja) * | 1981-10-15 | 1983-04-22 | Tanabe Seiyaku Co Ltd | 腸溶性マイクロカプセル |
| US4543886A (en) * | 1983-03-09 | 1985-10-01 | Intamin Inc. | Amusement ride including a rotating loading terminal |
| DK62184D0 (da) * | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
| CH658188A5 (de) * | 1984-03-23 | 1986-10-31 | Ciba Geigy Ag | Lagerstabile schnellzerfallende pharmazeutische presslinge. |
| CH666405A5 (de) * | 1985-06-24 | 1988-07-29 | Ciba Geigy Ag | Feste, haltbare darreichungsformen mit elastischem filmueberzug. |
| GB8521494D0 (en) * | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
-
1985
- 1985-07-31 GB GB858519310A patent/GB8519310D0/en active Pending
-
1986
- 1986-07-22 PH PH34052A patent/PH23531A/en unknown
- 1986-07-23 LU LU86523A patent/LU86523A1/de unknown
- 1986-07-23 US US06/888,610 patent/US4728513A/en not_active Expired - Fee Related
- 1986-07-24 CH CH3001/86A patent/CH670566A5/de not_active IP Right Cessation
- 1986-07-25 GB GB8618153A patent/GB2178313B/en not_active Expired
- 1986-07-28 DE DE19863625458 patent/DE3625458A1/de not_active Withdrawn
- 1986-07-28 FI FI863074A patent/FI863074A7/fi not_active Application Discontinuation
- 1986-07-28 IL IL79537A patent/IL79537A/xx unknown
- 1986-07-29 IT IT48323/86A patent/IT1195985B/it active
- 1986-07-29 SE SE8603247A patent/SE8603247L/ not_active Application Discontinuation
- 1986-07-29 FR FR868610952A patent/FR2585570B1/fr not_active Expired - Lifetime
- 1986-07-29 PT PT83093A patent/PT83093B/pt not_active IP Right Cessation
- 1986-07-29 ES ES8600694A patent/ES2000577A6/es not_active Expired
- 1986-07-30 GR GR862017A patent/GR862017B/el unknown
- 1986-07-30 NL NL8601961A patent/NL8601961A/nl not_active Application Discontinuation
- 1986-07-30 HU HU863240A patent/HU196304B/hu not_active IP Right Cessation
- 1986-07-30 AU AU60685/86A patent/AU596804B2/en not_active Ceased
- 1986-07-30 BE BE0/216995A patent/BE905200A/fr not_active IP Right Cessation
- 1986-07-30 ZA ZA865691A patent/ZA865691B/xx unknown
- 1986-07-30 AT AT2056/86A patent/AT392901B/de not_active IP Right Cessation
- 1986-07-30 DK DK361786A patent/DK361786A/da not_active Application Discontinuation
- 1986-07-30 JP JP61177897A patent/JPS6229514A/ja active Pending
- 1986-07-30 NZ NZ217028A patent/NZ217028A/xx unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01502754A (ja) * | 1987-03-27 | 1989-09-21 | ザ ウエルカム フアウンデーション リミテッド | 薬学的製剤 |
| JP2007510516A (ja) * | 2003-11-10 | 2007-04-26 | コナー メドシステムズ， インコーポレイテッド | 複数溶剤システムによって形成された有益な作用物質マトリクスを有する拡張可能医療デバイス |
| WO2006059716A1 (ja) * | 2004-12-03 | 2006-06-08 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| JP5283623B2 (ja) * | 2007-07-17 | 2013-09-04 | 旭化成ケミカルズ株式会社 | 水系組成物 |
| US8765187B2 (en) | 2007-07-17 | 2014-07-01 | Asahi Kasei Chemicals Corporation | Aqueous composition |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6229514A (ja) | 医薬活性物質の遅延放出形粒状物及びその製造方法 | |
| US4900557A (en) | Pellet formulation | |
| JP4436475B2 (ja) | 固体の経口用薬剤形のための結合剤または被覆の製造に適当な水性分散液、該水性分散液の使用および再分散性粉末 | |
| JP3707831B2 (ja) | デュロキセチン腸溶性ペレット | |
| Lavanya et al. | Pelletization technology: a quick review | |
| JPS60209518A (ja) | 貯蔵安定性を有し急速に崩壊する薬学的に活性な物質を含有する圧縮成形体及びその製造方法 | |
| JP2514078B2 (ja) | 圧縮成型製剤 | |
| WO1996019200A1 (en) | Sustained-release granular preparation and process for producing the same | |
| JPH05221854A (ja) | 水溶性薬物を含有する制御的放出錠剤 | |
| BRPI0721654A2 (pt) | formas de dosagem sàlida compreendendo um revestimento entÉrico com liberaÇço acelerada do fÁrmaco | |
| JPH0530804B2 (en, 2012) | ||
| HU226492B1 (en) | Enteric coated pharmaceutical tablet containing didanoside | |
| GB2087235A (en) | A granular delayed-release form of pharmaceutical active substances | |
| JP7551182B2 (ja) | 難溶性薬剤の経口徐放性組成物およびその調製方法 | |
| Alhalmi et al. | Sustained release matrix system: an overview | |
| JPS6248618A (ja) | 徐放性製剤およびその製造法 | |
| JPS6037093B2 (ja) | 被覆組成物 | |
| JP2004507487A (ja) | 腸疾患治療薬 | |
| JPH03500288A (ja) | 徐放性ニフェジピン製剤 | |
| JPH0813736B2 (ja) | 単斜結晶構造を有する熱―、光―、及び湿気―感受性活性成分を含む錠剤又は糖剤組成物の調製方法 | |
| CA2757752A1 (en) | Process for producing rapidly disintegrating spheroids (pellets), granules and/or mixtures thereof | |
| JPWO2002034268A1 (ja) | ５−アセチル−４，６−ジメチル−２−［２−［４−（２−メトキシフェニル）ピペラジニル］エチルアミノ］ピリミジン・三塩酸塩を有効成分として含有する徐放性製剤 | |
| PL193028B1 (pl) | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu chlorku potasu oparte na granulkach o wysokiej zawartości składnika aktywnego oraz sposób ich wytwarzania | |
| JPH01313431A (ja) | ジルチアゼム・マイクロビーズ、その製法および徐放性医薬組成物 | |
| JPS63222112A (ja) | 徐放性顆粒 |